Finally, we tested other genes in the SMAD pathway and showed that the treatment with artemether significantly decreased fibrogenic gene expressions in the NASH mouse liver, including smad2, Timp1, and Actaα (Figure 7H). The gene discussed is SMAD2; the disease is metabolic dysfunction-associated steatohepatitis.